

Christian Ruff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4651564/publications.pdf>

Version: 2024-02-01

89
papers

17,945
citations

109137

35
h-index

49773

87
g-index

90
all docs

90
docs citations

90
times ranked

16598
citing authors

#	ARTICLE	IF	CITATIONS
1	Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. American Heart Journal, 2022, 245, 29-40.	1.2	4
2	Association of Apolipoprotein Bâ€‘Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology, 2022, 7, 250.	3.0	108
3	Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal, 2022, 247, 24-32.	1.2	6
4	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
5	Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine, 2022, 28, 450-451.	15.2	4
6	Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nature Medicine, 2022, 28, 89-95.	15.2	24
7	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 695-706.	1.4	5
8	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS ONE, 2022, 17, e0266615.	1.1	5
9	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58Â634 patients across four randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f40-f49.	1.4	13
10	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
11	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal, 2021, 233, 48-58.	1.2	11
12	Biomarkers for Risk Assessment in Atrial Fibrillation. Clinical Chemistry, 2021, 67, 87-95.	1.5	16
13	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2021, 121, 140-149.	1.8	22
14	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	1.6	6
15	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation, 2021, 143, 673-684.	1.6	10
16	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2021, 42, 1698-1706.	1.0	27
17	Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. PLoS ONE, 2021, 16, e0248134.	1.1	11
18	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 77, 1197-1207.	1.2	29

#	ARTICLE	IF	CITATIONS
19	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 294-300.	0.8	5
20	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. <i>American Heart Journal</i> , 2021, 235, 132-139.	1.2	3
21	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
22	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 3005-3014.	1.1	6
23	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. <i>Circulation</i> , 2020, 141, 616-623.	1.6	143
24	Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase) Tj ETQq0 0 0 rgBT /Overlock 10 e264.	1.6	1
25	Association of APOE genotype and lipid lowering with cognitive function in a randomized placebo-controlled trial of Evolocumab. <i>Alzheimer's and Dementia</i> , 2020, 16, e047188.	0.4	0
26	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006511.	0.9	6
27	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	0.6	18
28	Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective. <i>Heart Rhythm</i> , 2020, 17, 1804-1832.	0.3	38
29	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , 2020, 141, 1600-1607.	1.6	61
30	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020, 304, 185-191.	0.8	25
31	The Promise of Mobile Health in Managing Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1535-1537.	1.2	2
32	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. <i>International Journal of Cardiology</i> , 2020, 317, 159-166.	0.8	2
33	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019, 74, 597-605.	1.3	16
34	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019, 140, 1792-1801.	1.6	22
35	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1381.	3.8	144
36	Response. <i>Chest</i> , 2019, 155, 1307.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Response. Chest, 2019, 155, 1309.	0.4	1
38	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 2019, 139, 2516-2527.	1.6	224
39	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
40	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. European Journal of Heart Failure, 2019, 21, 1571-1579.	2.9	44
41	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1518-1527.	1.0	67
42	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 380, 347-357.	13.9	4,159
43	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation, 2019, 139, 760-771.	1.6	99
44	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 2019, 139, 366-375.	1.6	32
45	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace, 2019, 21, 306-312.	0.7	6
46	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. European Heart Journal, 2019, 40, 1541-1550.	1.0	88
47	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	1.2	8
48	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2018, 257, 102-107.	0.8	18
49	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thrombosis and Haemostasis, 2018, 118, 1001-1008.	1.8	18
50	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	6.3	70
51	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 1466-1475.	1.2	10
52	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation, 2018, 138, 1963-1973.	1.6	32
53	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	13.9	205
54	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718

#	ARTICLE	IF	CITATIONS
55	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw565.	1.0	37
56	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	139
57	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 324.	3.0	28
58	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
59	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382.	1.2	111
60	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
61	Personalized Anticoagulation. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	8
62	First experience with edoxaban and atrial fibrillation ablation – Insights from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2017, 244, 192-195.	0.8	19
63	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30
64	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	53
65	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
66	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 537-544.	1.2	29
67	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178.	1.2	133
68	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1019-1034.	0.9	9
69	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	1.0	83
70	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	93
71	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016, 134, 24-36.	1.6	234
72	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , 2016, 129, 850-857.e2.	0.6	58

#	ARTICLE	IF	CITATIONS
73	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 (ENGAGE AF—TIMI 48) trial. <i>American Heart Journal</i> , 2016, 172, 144-151.	1.2	13
74	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, 1470-1477.	1.0	47
75	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2288-2295.	6.3	335
76	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF—TIMI 48 trial. <i>American Heart Journal</i> , 2015, 170, 1140-1150.	1.2	26
77	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2280-2287.	6.3	153
78	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , 2014, 35, 1457-1465.	1.0	174
79	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. <i>Stroke</i> , 2014, 45, 2372-2378.	1.0	46
80	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014, 383, 955-962.	6.3	3,942
81	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418.	0.8	64
82	Transition of Patients From Blinded Study—Drug to Open-Label Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 576-584.	1.2	39
83	Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 361-367.	1.0	18
84	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
85	Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2012, 125, e588-90.	1.6	4
86	Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. <i>International Journal of Cardiology</i> , 2012, 155, 424-429.	0.8	10
87	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillation—Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF—TIMI 48). <i>American Heart Journal</i> , 2010, 160, 635-641.e2.	1.2	439
88	TIMI Risk Index and the Benefit of Enoxaparin in Patients with ST-Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2007, 120, 993-998.	0.6	9
89	Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. <i>Future Cardiology</i> , 2006, 2, 85-91.	0.5	1